Annual Meeting

AM17 Daily News Monday

Contents of this Issue

Navigation

Page 0 of 119

said. Research has also shown
that systemic symptom moni-
toring can help close this gap,
and that patients are willing and
able to self-report, even when
they are ill or close to death.
The standard model for re-
porting symptoms is a reactive
approach in which patients
must take the initiative to re-
member and report their symp-
toms to health professionals,
who can then take action to al-
leviate the symptoms, Dr. Basch
noted. In a proactive model,
and closed January 2014. En-
rolled patients included those
with high-risk locally advanced
or metastatic prostate cancer
that was newly diagnosed or
relapsed after radical prostatec-
tion. Patients were randomly
assigned 2:1 to receive olapa-
rib 300 mg tablets twice daily
(205 patients) or to physician's
choice of chemotherapy (97 pa-
tients; 91 treated). The tablet
formation was developed for
patient convenience, and repre-
sents a slightly lower dose than
the commonly available dose of
400 mg, taken in 8 capsules.
Patient characteristics were
well-matched between the
groups, with a median age of
44 and 45, respectively; most
patients were white (65%), and
about half of the patients had
triple-negative breast cancer
(TNBC). The most commonly
used chemotherapy agents in-
cluded capecitabine, eribulin,
and vinorelbine.
The study met its primary
endpoint of progression-free
survival (PFS), assessed by
blinded independent central re-
view. The patients treated with
olaparib had a median PFS of
7.0 months compared with 4.2
months with chemotherapy
(hazard ratio [HR] 0.58, 95% CI
MEETING COVERAGE
Genomics and Bladder
Cancer Treatment 8A
Risk-Based Approach to
Colon Cancer Chemotherapy
Duration 18A
Early Drug Development
for Sarcoma 18A
Combined Checkpoint
Inhibition and CNS Therapy
in Melanoma 21A
In Brief 21A
Post-Surgery Capecitabine
New Standard of Care in
Biliary Tract Cancers 22A
Front-Line Bendamustine
Plus Rituximab in Indolent
NHL and MCL 23A
Fluciclovine in Cancer
Management 1B
Treatment of Older Patients
With Lung Cancer 1C
Must-See Monday and
Tuesday Sessions 1D
PHYSICIAN-AUTHORED
Expert Editorials
ASCO and FDA's Efforts to
Improve the Evidence Base
for Treating Older Adults
With Cancer 10A
Pathways and Practice
Transformation 12A
Consensus Guidelines for
Breast-Conserving Surgery 1B
Improving International
Quality Standards for
Oncology Care 20B
Circulating Tumor DNA
as Precision Medicine
Tool for Lymphoma 26B
Gene Editing by CRISPR/
CAS9 in Human Cells 1C
Tobacco Control 32C
Clinical Corner
First-Line Therapy in
Advanced BRAF-Mutant
Melanoma 35B
Surgery After Neoadjuvant
Chemotherapy in Advanced
Gastric Cancer 3C
ASCO NEWS
CENTRA 10A
2011 Plenary Retrospective 3B
2017 GU Cancers
Symposium Highlights 14B
2017 Cancer Survivorship
Symposium Highlights 18C
Increasing Workforce
Diversity in Oncology 24C
SPECIAL AWARDS
Award for Excellence in
Geriatric Oncology: Dr.
Jean-Pierre Droz 1B
Allen S. Lichter Visionary
Leader Award: Dr. Patrick
J. Loehrer 1C
HIGHLIGHTS
ASCO Daily News session
coverage continues online.
Visit am.asco.org/dn
for exclusive coverage
of Monday and Tuesday
sessions.
Attendee
Tip of the Day
See ADT Plus Abiraterone, Page 3A
DAILY NEWS
MONDAY · J U N E 5, 20 1 7
A
See Olaparib, Page 3A
See Reporting Symptoms Tool, Page 8A
ADT Plus Abiraterone Improves Survival in
Hormone-Sensitive Advanced Prostate Cancer
A
dding abiraterone to
androgen-deprivation
therapy (ADT) in-
creased overall survival
(OS) among men with locally
advanced or hormone-sensitive
metastatic prostate cancer, and
the therapy was well tolerated,
according to results presented
from the LATITUDE (Abstract
LBA3) and STAMPEDE trials
(Abstract LBA5003).
"Abiraterone acetate plus
prednisolone should be part of
the standard of care for men
starting long-term ADT," Nicho-
las D. James, BSc, MBBS, PhD,
of Queen Elizabeth Hospital
and the University of Birming-
ham, in the United Kingdom,
said. He presented the results of
the STAMPEDE trial during the
Genitourinary (Prostate) Cancer
Oral Abstract Session on June 3.
Approximately 3% to 5% of
men diagnosed with prostate
cancer have metastasis at diag-
nosis in Western countries; in
some large countries in Asia,
however, that incidence can be
as high as 60%, Karim Fizazi,
MD, PhD, of the Gustave Roussy
Cancer Campus and University
Paris-Sud, in France, said during
an ASCO Press Briefing on June
3. Dr. Fizazi presented results
of the LATITUDE trial during
the Plenary Session on June 4.
Historically, ADT has been the
standard of care for patients
with hormone-sensitive, locally
advanced or metastatic disease,
and in the past several years
docetaxel has been added to
that therapy for patients with
high metastatic burden.
STAMPEDE Trial
The STAMPEDE trial began in
2005 and is the largest random-
ized clinical trial of treatments
for prostate cancer. This on-
going study has a multistage,
multi-arm design to allow adap-
tion and addition of new thera-
pies. An abiraterone compari-
son arm was opened in 2011
Olaparib Improves Outcomes
in BRCA-Mutated Metastatic
Breast Cancer
Online Tool for Reporting
Symptoms Extends Survival
O
laparib tablet mono-
therapy yielded im-
proved progression-free
survival compared with
standard-of-care chemotherapy
among women with HER2-
negative metastatic breast can-
cer and a germline BRCA muta-
tion, according to results of a
phase III trial (Abstract LBA4).
Mark E. Robson, MD, of Me-
morial Sloan Kettering Cancer
Center, presented the results
of the Olympiad trial during
the Plenary Session held June
4. Inhibition of poly (ADP-ri-
bose) polymerase (PARP) when
BRCA1/2 mutations are not
present to aid in DNA damage
repair can induce "synthetic
lethality" in cancer cells, and
some small studies suggested
that PARP inhibition could be
effective in patients with breast
cancer when BRCA mutations
are present, he said during a
press briefing also held June 4.
Olympiad included 302 pa-
tients with HER2-negative
metastatic breast cancer with
a confirmed or suspected del-
eterious germline BRCA muta-
T
he use of a web-based sys-
tem that allowed patients
to report symptoms to
their clinicians remotely
was associated with benefits in-
cluding improved quality of life
(QOL) and longer overall sur-
vival (OS), a randomized single-
center trial found.
Ethan M. Basch, MD, MSc,
FASCO, of The University of
North Carolina at Chapel Hill,
presented the findings of the
study (Abstract LBA2) at the Ple-
nary Session on June 4. "This
approach should be considered
for inclusion as a part of stan-
dard symptom management,"
Dr. Basch said. The results of the
study were published in the Jour-
nal of the American Medical Asso-
ciation simultaneously with the
presentation.
Symptoms are common in
advanced cancer, and symptom
management is a cornerstone of
oncology practice to alleviate
suffering and avoid downstream
complications. However, nu-
merous hurdles inhibit patient
reporting of symptoms, and pre-
vious research has shown that
up to half of symptoms are not
reported to clinicians, Dr. Basch
Dr. Karim Fizazi
presents LBA3.